Make Your Voice Heard
If you have primary biliary cholangitis (formerly known as primary biliary cirrhosis) or PBC or are caring for someone who has PBC, we would like to hear from you.
Health Canada is currently reviewing a new drug therapy -- obeticholic acid
or OCA -- for PBC. As part of their review, Health Canada wants to hear from liver disease patients, caregivers and health care professionals to get a sense of the personal impact of this disease, how currently available treatments are working or not working and what outcomes are most important. when considering potential new treatments.
The Canadian Liver Foundation is preparing a submission and we invite you to be part of it by sharing your comments and personal experiences.
Please note that the CLF does not recommend any particular drug for the treatment of PBC. We believe that patients and their doctors should have access to a broad range of treatment options in order to ensure the best possible outcomes. It is up to the doctors to make individual treatment recommendations based on the needs of their patients. Our request for input for obeticholic acid is the result of a call for patient group input from Health Canada.
If you have experience with PBC and would like to share your comments, please click on the link below and fill out our survey. We will compile all feedback and include it in our submission to Health Canada.
Canadian Liver Foundation survey on obeticholic acid.
The deadline for submitting your comments is 5:00pm (EDT) on Monday, January 9, 2017.
If you have any questions about the survey or the Canadian Liver Foundation's submission to Health Canada, please contact Melanie Kearns at 1-800-563-5483 or email email@example.com